Predictive ability of direct-to-consumer pharmacogenetic testing: when is lack of evidence really lack of evidence?

Author： Kalf Rachel RJ   Bakker Rachel   Janssens A Cecile JW  

Publisher： Future Medicine

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.14, Iss.4, 2013-03, pp. : 341-344

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Little evidence for benefits with direct-to-consumer advertising

By  

Inpharma, Vol. 1, Iss. 1582-1583, 2007-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Little evidence for benefits with direct-to-consumer advertising

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 528, 2007-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Direct-to-consumer pharmacogenomic testing

By Howard Heidi Carmen   Borry Pascal  

Pharmacogenomics, Vol. 12, Iss. 10, 2011-10 ,pp. : 1367-1370

Future Medicine

Access to resources Recommend Favorite

Direct-to-consumer genome testing: opportunities for pharmacogenomics research?

By Prainsack Barbara   Wolinsky Howard  

Pharmacogenomics, Vol. 11, Iss. 5, 2010-05 ,pp. : 651-655

Future Medicine

Access to resources Recommend Favorite

Muscarinic receptor subtypes in the human colon: lack of evidence for atypical subtypes

By Mansfield K.J.   Mitchelson F.J.   Moore K.H.   Burcher E.  

European Journal of Pharmacology, Vol. 482, Iss. 1, 2003-12 ,pp. : 101-109

Elsevier

Access to resources Recommend Favorite